Firebrick Pharma Limited (ASX:FRE) has advised that all nine resolutions put to shareholders at its Annual General Meeting, held on 11 November 2026 at 11:00am AEDT, were passed on a poll, including a special resolution approving a 7.1A mandate.

Key Points

  • All nine resolutions were passed on a poll at the Annual General Meeting held 11 November 2026.
  • Resolution 3, the Approval of 7.1A Mandate, was passed as a special resolution by a sufficient majority, with 99.92% of poll votes in favour.
  • Director incentive options were approved for Peter Molloy, Stephen Goodall, Rick Legleiter, and Al Moghaddam.
  • Al Moghaddam was elected as a director, with 99.92% of poll votes cast in favour.
  • The meeting also approved the adoption of the Remuneration Report, appointment of an auditor, and the issue of awards under the Employee Securities Incentive Plan.

Annual General Meeting Voting Results

All resolutions put to members at Firebrick Pharma's Annual General Meeting on 11 November 2026 were carried. Voting was conducted by poll across all nine resolutions. Resolution 1, the adoption of the Remuneration Report, received 99.80% of poll votes in favour, with 82,014 votes against. Resolution 9, the appointment of auditor, received 99.94% of poll votes in favour. Resolution 8, approving issues under the Company's Employee Securities Incentive Plan, was carried with 98.89% of poll votes in favour. The filing states the results were prepared in accordance with section 251AA of the Corporations Act 2001.

Director Election and Incentive Option Approvals

The election of Al Moghaddam as a director was carried, with 103,195,186 votes, representing 99.92% of poll votes, cast in favour, and 82,183 votes against. Shareholder approval was also granted for the issue of director incentive options to four individuals: Executive Chairman Peter Molloy, with 99.44% of poll votes in favour; Stephen Goodall, with 99.45% in favour; Rick Legleiter, with 99.62% in favour; and Al Moghaddam, with 99.62% in favour. Each of the four incentive option resolutions recorded 395,429 votes against.

Special Resolution: 7.1A Mandate Approval

Resolution 3, seeking approval of a 7.1A Mandate, was passed as a special resolution by a sufficient majority. According to the filing, the poll recorded 103,174,758 votes in favour, representing 99.92% of votes cast, with 82,864 votes against and 71,598 abstentions. The release was authorised by Dr Peter Molloy, Executive Chairman of Firebrick Pharma Limited. Firebrick Pharma is described in the filing as developing and commercialising novel consumer health products based on povidone-iodine, with its Nasodine Nasal Spray launched in the United States, Singapore, and Fiji.